United Therapeutics (NASDAQ:UTHR) CEO Martine Rothblatt Sells 9,500 Shares of Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of the company’s stock in a transaction dated Wednesday, June 10th. The stock was sold at an average price of $545.83, for a total transaction of $5,185,385.00. Following the completion of the sale, the chief executive officer directly owned 40,513 shares of the company’s stock, valued at $22,113,210.79. The trade was a 19.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

United Therapeutics Stock Up 0.2%

United Therapeutics stock opened at $545.40 on Friday. United Therapeutics Corporation has a twelve month low of $272.12 and a twelve month high of $609.35. The firm has a 50 day moving average price of $567.24 and a 200-day moving average price of $521.17. The company has a market capitalization of $23.15 billion, a P/E ratio of 20.13, a P/E/G ratio of 1.77 and a beta of 0.57.

United Therapeutics (NASDAQ:UTHR) last released its earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share for the quarter, missing analysts’ consensus estimates of $7.00 by ($1.18). United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. The company had revenue of $781.50 million for the quarter, compared to the consensus estimate of $797.40 million. During the same period in the prior year, the company earned $6.63 earnings per share. The firm’s revenue was down 1.6% on a year-over-year basis. Equities analysts expect that United Therapeutics Corporation will post 26.84 EPS for the current fiscal year.

Institutional Investors Weigh In On United Therapeutics

Hedge funds have recently bought and sold shares of the business. Torren Management LLC bought a new stake in United Therapeutics during the fourth quarter worth about $26,000. Activest Wealth Management lifted its position in United Therapeutics by 1,400.0% during the fourth quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock valued at $29,000 after purchasing an additional 56 shares during the period. WealthCollab LLC lifted its position in United Therapeutics by 55.9% during the second quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock valued at $30,000 after purchasing an additional 38 shares during the period. Rakuten Securities Inc. lifted its position in United Therapeutics by 76.7% during the second quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock valued at $30,000 after purchasing an additional 46 shares during the period. Finally, Entrust Financial LLC bought a new position in United Therapeutics during the fourth quarter valued at approximately $31,000. Institutional investors own 94.08% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms recently commented on UTHR. Wells Fargo & Company raised shares of United Therapeutics from an “equal weight” rating to an “overweight” rating and raised their price objective for the stock from $575.00 to $735.00 in a report on Thursday, May 7th. Cantor Fitzgerald raised their price objective on shares of United Therapeutics from $525.00 to $625.00 and gave the company an “overweight” rating in a research report on Thursday, March 12th. Bank of America lifted their target price on shares of United Therapeutics from $569.00 to $626.00 and gave the stock a “neutral” rating in a research report on Tuesday, March 31st. HC Wainwright lifted their target price on shares of United Therapeutics from $600.00 to $660.00 and gave the stock a “buy” rating in a research report on Tuesday, March 31st. Finally, Morgan Stanley set a $516.00 price objective on shares of United Therapeutics in a research report on Thursday, May 7th. Eleven investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $619.42.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.